Transduction Efficiency of Adenovirus Vectors in Endothelial Cells and Vascular Smooth Muscle Cells
Nikita Mokhashi(Temple University), Satoru Eguchi(University of South Florida), Yayoi Kimura(Yokohama City University Medical Center), Tomoko Akiyama(Yokohama City University Medical Center), Michael Boyer(Chris O’Brien Lifehouse), Hannah Cooper(Temple University), Rosario Scalia(Temple University), Robert Y. Choi(Temple University), Victor Rizzo(Temple University), Kunie Eguchi(Vanderbilt University), Stephanie Cicalese(Temple University)
Cited by 9
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
|Physiological Reviews|2018|1.1k